All In Biotech

Drug Trial Radar · NCT06429930

Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults

A Phase 1, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 for Inhalation in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Apr 11, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Pharmosa Biopharm Inc.Industry
Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
May 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.

Conditions

  • Healthy Adult Participants

Interventions

  • L608 Liposomal inhalation suspensionDrug

    Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.

  • Placebo SolutionDrug

    Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with DLTTime frame: 7 days after administration
  2. Percentage of participants with TEAEs and SAEsTime frame: 2 weeks after administration
  3. Frequency and severity of TEAEs and SAEsTime frame: 2 weeks after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NZCR Ltd (New Zealand Clinical Research)

    Christchurch, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.